Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deoxyspergualin in Islet Transplantation for Type 1 Diabetes
NCT00434850Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2006
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deoxyspergualin in type 1 diabetes mellitus (T1D), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of Insulin-independent Subjects at 75 days. Started Oct 2006; status: completed.
02
Drugs
deoxyspergualin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00434850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00434850.